• Explore /
  • Poster
  • / Trastuzumab versus MYL-1401O (a proposed trastuzumab biosimilar) in a phase I bioequivalence study: In vivo and in vitro immunomodulation.

Trastuzumab versus MYL-1401O (a proposed trastuzumab biosimilar) in a phase I bioequivalence study: In vivo and in vitro immunomodulation.

Abstract Poster

Authors

null

Régine Audran

Division of Immunology and Allergy- CHUV- University Hospital, Lausanne, Switzerland

Régine Audran, Haithem Chtioui, Anne-Christine Thierry, Carole Mayor, Laure Vallotton, Kim Dao, Laura Rothuizen, Ali Maghraoui, Eduardo J. Pennella, Françoise Brunner-Ferber, Thierry Buclin, Francois Spertini

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells

Sub Track

Clinical Trials

Clinical Trial Registration Number

2011-001406-94

Citation

J Clin Oncol 35, 2017 (suppl 7S; abstract 10)

DOI

10.1200/JCO.2017.35.7_suppl.10

Abstract #

10

Poster Bd #

B3

Abstract Disclosures

Similar Posters

First Author: Nicola Maurea

First Author: Rongsu Qi

First Author: Nicola Maurea

First Author: Giulia Pasello